Published in J Manag Care Pharm on October 01, 2008
Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay. Ann Pharmacother (2007) 1.95
Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States. Pain Med (2014) 1.79
Validity of self-reported smoking status among participants in a lung cancer screening trial. Cancer Epidemiol Biomarkers Prev (2006) 1.59
Prediction of first events of coronary heart disease and stroke with consideration of adiposity. Circulation (2008) 1.56
A perspective on the epidemiology of acetaminophen exposure and toxicity in the United States. Expert Rev Clin Pharmacol (2014) 1.18
The societal costs of low back pain: data published between 2001 and 2007. J Pain Palliat Care Pharmacother (2007) 1.14
Employing external facilitation to implement cognitive behavioral therapy in VA clinics: a pilot study. Implement Sci (2010) 1.12
The impact of obesity on diabetes, hyperlipidemia and hypertension in the United States. Qual Life Res (2008) 1.11
Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother (2006) 1.02
Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptions. Pain Pract (2010) 1.02
Cost, morbidity, and control of asthma in Hungary: The Hunair Study. J Asthma (2003) 1.02
Clinical risk factors for fracture in postmenopausal osteoporotic women: a review of the recent literature. Ann Pharmacother (2008) 1.01
Application of electronic medical record data for health outcomes research: a review of recent literature. Expert Rev Pharmacoecon Outcomes Res (2013) 1.01
A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther (2002) 1.00
Economic costs of obesity to self-insured employers. J Occup Environ Med (2008) 0.99
Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis. Pharmacoeconomics (2009) 0.95
The impact of overweight and obesity on the direct medical costs of truck drivers. J Occup Environ Med (2009) 0.94
Development of a practical screening tool to predict low muscle mass using NHANES 1999-2004. J Cachexia Sarcopenia Muscle (2013) 0.90
Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US. J Med Econ (2014) 0.89
An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation. J Occup Environ Med (2007) 0.87
Cost-effectiveness of insulin analogs. Am J Manag Care (2008) 0.86
Use of prescription opioids with abuse-deterrent technology to address opioid abuse. Curr Med Res Opin (2014) 0.86
Pharmacist-provided diabetes management and education via a telemonitoring program. J Am Pharm Assoc (2003) (2015) 0.84
Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids. Pain Pract (2011) 0.84
Health economics perspective of the components of the cardiometabolic syndrome. J Clin Hypertens (Greenwich) (2010) 0.84
Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy (2012) 0.84
Real-world evidence in pain research: a review of data sources. J Pain Palliat Care Pharmacother (2014) 0.81
Economic impact of potential drug-drug interactions in opioid analgesics. J Med Econ (2011) 0.81
The Utah Remote Monitoring Project: improving health care one patient at a time. Diabetes Technol Ther (2014) 0.80
Clinical risk factors for fracture among postmenopausal patients at risk for fracture: a historical cohort study using electronic medical record data. J Bone Miner Metab (2010) 0.80
Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance. J Antimicrob Chemother (2008) 0.79
Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis. Drugs Aging (2008) 0.79
Cost and comorbidities associated with opioid abuse in managed care and Medicaid patients in the United Stated: a comparison of two recently published studies. J Pain Palliat Care Pharmacother (2010) 0.79
Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation. J Manag Care Pharm (2013) 0.79
Sources of prescription opioids among diagnosed opioid abusers. Curr Med Res Opin (2015) 0.79
Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids. Pain Pract (2011) 0.78
Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data. Appl Health Econ Health Policy (2014) 0.78
Characteristics of High-Cost Patients Diagnosed with Opioid Abuse. J Manag Care Spec Pharm (2015) 0.78
Predictors of metabolic parameter monitoring in adolescents on antipsychotics in a primary care setting. Ment Health Fam Med (2012) 0.77
Assessment of time to follow-up visits in newly-treated hypertensive patients using an electronic medical record database. Curr Med Res Opin (2010) 0.77
Impact of body mass index on the incidence of cardiometabolic risk factors in ambulatory care settings over 5 years or more. Value Health (2009) 0.77
Metabolic monitoring of patients prescribed second-generation antipsychotics. J Psychiatr Pract (2013) 0.77
Characterization of patients undergoing total hip arthroplasty in a real-world setting and pain-related medication prescriptions for management of postoperative pain. J Pain Palliat Care Pharmacother (2013) 0.77
Characterization of patients undergoing total knee arthroplasty in a real-world setting and pain-related medication prescriptions for management of postoperative pain. J Pain Palliat Care Pharmacother (2012) 0.76
Opioid use in the management of diabetic peripheral neuropathy (DPN) in a large commercially insured population. Clin J Pain (2015) 0.75
Systematic review on quality control for drug management programs: is quality reported in the literature? BMC Health Serv Res (2009) 0.75
Treatment of type 1 and type 2 diabetes mellitus with insulin detemir, a long-acting insulin analog. Clin Med Insights Endocrinol Diabetes (2010) 0.75
Health-care resource use by asthmatics in Croatia. J Asthma (2002) 0.75
Tobacco cessation treatment knowledge, attitudes and practices of Kentucky physicians. J Ky Med Assoc (2007) 0.75
National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom. Int J Cardiol (2003) 0.75
Predicting medication persistence to buprenorphine transdermal system. Pain Pract (2014) 0.75
The economic burden of diagnosed opioid abuse among commercially insured individuals. Postgrad Med (2014) 0.75
Use of the SF-36v2 Health Survey as a Screen for Risk of Major Depressive Disorder in a US Population-based Sample and Subgroup With Chronic Pain. Med Care (2017) 0.75
Cardiometabolic risk and health care utilization and cost for Hispanic and non-Hispanic women. Popul Health Manag (2009) 0.75
Once-weekly exenatide as a treatment for Type 2 diabetes. Expert Rev Cardiovasc Ther (2015) 0.75
US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system. Curr Med Res Opin (2014) 0.75
Patent extension policy for paediatric indications: an evaluation of the impact within three drug classes in a state Medicaid programme. Appl Health Econ Health Policy (2011) 0.75
Association between second-generation antipsychotics and changes in body mass index in adolescents. J Adolesc Health (2013) 0.75
Problems in studying the association between race and pain in outcomes research. J Pain Palliat Care Pharmacother (2007) 0.75
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY. Endocr Pract (2017) 0.75
Team-based approach to addressing simvastatin safety concerns. J Am Pharm Assoc (2003) (2013) 0.75